Yellow Fever Vaccine Access

Sanofi Pasteur confirms that YF-VAX® (Yellow Fever Vaccine) is unavailable to order in the U.S. until mid-2018 as the company transitions production to a new state-of-the-art facility, which is expected to occur in 2018.

Sanofi Pasteur has worked with the FDA to make another yellow fever vaccine available in the US through an Expanded Access Investigational New Drug Application (IND). Manufactured by Sanofi Pasteur in France, this vaccine, STAMARIL® (Yellow Fever Vaccine [Live]), is registered and distributed in over 70 countries. However, it is considered investigational in the US, as it is not a US-licensed product.

The Expanded Access Program has requirements similar to a clinical trial; thus Sanofi Pasteur can support only a limited number of sites. Working closely with the CDC, geographically distributed sites throughout the US were identified for inclusion in the program so patients can have continued access to yellow fever vaccine.

Health care providers and patients may find locations that can administer STAMARIL vaccine by visiting the CDC web page at New clinics will be continually added as they complete the certification process.

Providers and patients may also visit for information about which countries require yellow fever vaccination for entry and for which countries the CDC recommends yellow fever vaccination.


PDFSTAMARIL Patient Leaflet


For Further Information About Yellow Fever:

(1) Centers for Disease Control & Prevention:

External LinkMMWR


(2) Centers for Disease Control & Prevention:

External Link


(3) World Health Organization:

External Link